2026. IMMUNE CHECKPOINT INHIBITORS IN SOLID TUMORS: MECHANISMS, CLINICAL EFFICACY, BIOMARKER-GUIDED PATIENT SELECTION, AND IMMUNE-RELATED ADVERSE EVENTS. Journal of Multidisciplinary Sciences and Innovations. 5, 03 (Mar. 2026), 1709–1714. DOI:https://doi.org/10.55640/.